Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $79.34, while State Street SPDR S&P Biotech ETF trades at $154.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares Core MSCI Emerging Markets ETF nearer its low. Which is the better fit depends on your goals.
| IEMG | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $86.00 | $164.28 |
52-Week Low | $59.90 | $85.16 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $77.21, up 0.3% with a bearish technical signal from moving averages and oscillators. The ETF shows strong recent performance with 35% gains over the past year, driven by emerging market inflows and AI-focused technology exposure. Recent news highlights record capital flows into emerging markets and IEMG's 40% technology weighting, though some analysts caution about elevated volatility and concentration risks.
The outlook remains mixed with attractive emerging market valuations and growth opportunities balanced against geopolitical risks and market volatility. Key catalysts include continued AI-driven technology performance and emerging market economic growth, while risks involve US-China tensions and potential market corrections given the ETF's recent strong run.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
